Concepedia

Author

Neil Bifulco

Blueprint Medicines (United States)

Also Known As

N. Bifulco, Neil Bifulco, Neil Bifulco Jr.

29

Publications

882

Citations

9

H-Index

16

Concepts

All Affiliations

Blueprint Medicines (United States)
NB

About

Neil Bifulco is an author at Blueprint Medicines (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

292

2

Health Sciences

1

1

262

3

Natural Sciences

1

1

30

4

Biochemistry

1

1

30

5

Chemical Biology

1

1

30

Neil Bifulco

×

6

Publications

728

Citations

6

H-Index

YearCitations

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael P. Sheets,

Cancer Discovery

2015

305

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir,

Nature Microbiology

2017

262

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Megan Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin,

Cancer Discovery

2019

106

The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: Hydroxyindole derivatives

Karen L. Milkiewicz, Thomas H. Marsilje, Richard P. Woodworth,

Bioorganic & Medicinal Chemistry Letters

2000

30

Substituted indanylacetic acids as PPAR-α–γ activators

Derek Lowe, Neil Bifulco, William H. Bullock,

Bioorganic & Medicinal Chemistry Letters

2005

14

Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in <i>CCNE1</i>-amplified ovarian cancer models

Victoria E. Brown, Phil Ramsden, Nealia C. House,

Cancer Research

2022

11

Page 1